Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AbbVie (NY: ABBV )

196.96 -0.52 (-0.26%)
Official Closing Price Updated: 4:10 PM EDT, Oct 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,774,964
Open 197.65
Bid (Size) 196.43 (2)
Ask (Size) 198.97 (1)
Prev. Close 197.48
Today's Range 196.42 - 198.97
52wk Range 135.85 - 199.95
Shares Outstanding N/A
Dividend Yield 3.01%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Transforming Alzheimer’s Treatment: Innovative Combinations to Boost Cognition
Via Investor Brand Network
Transforming Alzheimer’s Treatment: Innovative Combinations to Boost Cognition
EQNX::TICKER_START (NYSE:ANVS),(NYSE:LLY),(NYSE:PFE),(NYSE:NVO),(NASDAQ:ABBV) EQNX::TICKER_END 
Via FinancialNewsMedia

Performance

YTD
+23.24%
+23.24%
1 Month
-0.37%
-0.37%
3 Month
+15.61%
+15.61%
6 Month
+8.96%
+8.96%
1 Year
+32.86%
+32.86%

More News

Read More
Meta, Accenture, Disney And A Major Health Care Stock On CNBC's 'Final Trades'
Via Benzinga
(ABBV) - Analyzing AbbVie's Short Interest
Via Benzinga
Here's How Much You Would Have Made Owning AbbVie Stock In The Last 10 Years
Via Benzinga
15 Best Dividend Stocks for Lifelong Passive Income
Via The Motley Fool
Absence of Black Box Warning For Bristol Myers' Schizophrenia Treatment Could Enhance Alzheimer's Psychosis Potential
Via Benzinga
Exposures Product Safety
AbbVie Says Pivotal Trial For Parkinson's Candidate Meets Its Primary Goal In Patients With Early Disease
Via Benzinga
Forget Novo Nordisk, Buy This Magnificent Dividend Stock Instead
Via The Motley Fool
Behind the Scenes of AbbVie's Latest Options Trends
Via Benzinga
Spotlight on AbbVie: Analyzing the Surge in Options Activity
Via Benzinga
Competitor Analysis: Evaluating AbbVie And Competitors In Biotechnology Industry
Via Benzinga
Is ABBVIE INC Ready to Break Out of Its Range?
Via Chartmill
Bristol-Myers Acquired Drug KarXT Poised For FDA Approval As First New Type Of Schizophrenia Treatment In 70 Years
Via Benzinga
Exposures Product Safety
2024 Election: Drug Prices Remain A 'Hot Topic.' Can Pharma Stocks Withstand The Pressure?
Via Investor's Business Daily
2 Unstoppable S&P 500 Dividend Stocks to Buy Before They Beat the Market Again
Via The Motley Fool
Topics Stocks
Exposures US Equities
Abbie Inc Stocks Elliott Wave Technical Analysis - Wednesday, September 18,
Via Talk Markets
TransDigm, BJ's Wholesale, AbbVie And More On CNBC's 'Final Trades'
Via Benzinga
Topics ETFs
Can AbbVie Regain Its Status As a Top Dividend Growth Stock?
Via The Motley Fool
Investing in Biotech or Pharma Stocks? Pay Attention to These 3 Things and You'll Win More
Via The Motley Fool
3 Stocks to Buy and Hold Forever
Via The Motley Fool
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever
Via The Motley Fool
Time To Invest And Or Trade In Bio-Tech Stocks?
Via Talk Markets
Topics ETFs
Is This Company Still a Strong Buy After Tripling the S&P 500's Returns?
Via The Motley Fool
Topics Stocks
Exposures US Equities
UnitedHealth Follows Competitors, Replaces Humira with Lower-Cost Biosimilars
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.